http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
특정적 광과민성 피부증상 없이 우울증으로 입원한 전신성 홍반성 낭창 1례
최석채,이상열,박민철,나용호 圓光大學校 醫科學硏究所 1998 圓光醫科學 Vol.14 No.2
We experienced a 22-years-old female patient with systemic lupus erythematosus (SLE) who was admitted with major depressive disorder symptoms such as a depressive mood, loss of appetite, weight loss, insomnia, and fatigue. She did not show any characteristic photosensitive cutaneous symptoms of SLE when she came to the hospital. Antidepressants and psychotherapy under hospitalization did not show any improvements in her depressive symptoms. Her past history revealed Raynaud's phenomenon and arthralgia, leukopenia, normochronic normocytic anemia and elevated erythrocyte sedimentation rate were detected on her routine laboratory examinations. We considered an autoimmune connective tissue disease and performed specific hematologic and immunologic tests. We confirmed that her systemic symptoms and results of specific tests were fitted to a case of SLE, so we started prednisolone medication. After treating the patient with prednisolone for 2 weeks, her psychiatric and systemic symptoms of SLE were improved. We concluded that psychiatrists have to pay attention to SLE that can manifest depressive symptoms without characteristic photosensitive cutaneous symptoms of SLE.
Choi, Suck-Chei,Choi, Eun-Ju,Oh, Hyun-Mee,Lee, SungGa,Lee, Jeong-Kun,Lee, Meung-Su,Shin, Yong-Il,Choi, Suck-Jun,Chae, Jeong-Ryong,Lee, Kang-Min,Lee, Won-Jung,Park, Jae-Sik,Shin, Chang-Yell,Oh, Tae-You WJG Press 2006 WORLD JOURNAL OF GASTROENTEROLOGY Vol.12 No.30
<P>To investigate whether, or how, DA-9601, which is a new gastroprotective agent, inhibits TNF-alpha-induced inflammatory signals in gastric epithelial AGS cells.</P>
최석준 ( Suck Jun Choi ),채정룡 ( Jeong Ryong Chae ),문용식 ( Yong Shig Moon ),최태석 ( Tae Suck Choi ),심미령 ( Mi Ryeong Sim ),최석채 ( Suck Chei Choi ) 한국운동영양학회 2004 Physical Activity and Nutrition (Phys Act Nutr) Vol.8 No.2
The purpose of this study was to determine the effect of long distance running on the level of gastrointestinal hormones such as gastrin which stimulates the secretion of gastric acid, insulin and glucagon which affect glucose metabolism as well as the level of glucose. Method: Twenty four long distance runners (male 16, female 8) participated in this study. Studies were performed after an overnight fasting. The levels of gastrin, insulin, glucagon, and glucose in blood were measured at 30min before and after exercise, and then they were measured again at 24 hr after 10 km race. Result: Plasma gastrin level was increased immediately after exercise (p<0.05), while no significant changes were observed before and after 24 hours of exercise. Plasma insulin level was decreased immediately after exercise (p<0.05). Plasma glucagon level was elevated immediately after exercise (p<0.05). However, there was no significant difference in the level of plasma glucose level during the study period. Conclusion: These results indicate that the elevated level of gastrin in long distance runner may be involved in acid-related gastrointestinal disease. The changes of insulin and glucagon levels may represent the constant blood glucose level and further imply the fine regulatory mechanism of glucose homeostasis in blood during short time exercise in long distance runners.
Choi, Suck-Chei,Han, Weon-Cheol,Park, Do-Sim,Kim, Eun-Cheol,Oh, Hyun-Mee,Oh, Jung-Mi,Jun, Chang-Duk The Korean Society for Microbiology 2002 Journal of Bacteriology and Virology Vol.32 No.1
Intercellular adhesion molecule-1 (ICAM-1) is a membrane protein, exists as a dimer on the cell surface, and interacts with leukocyte function associated antigen-1 (LFA-1), a member of ${\beta}_2$-integrin family. A soluble circulating form of ICAM-1 (sICAM-1) is also detected in human serum, and has been implicated as a regulator for LFA-1-dependent cell-cell interaction in vivo. However, previous reports demonstrated that sICAM-1 shows little inhibitory effect on LFA-1 binding to ICAM-1, indicating that sICAM-1 is unlikely to antagonize LFA-1/ICAM-1-mediated cellular events in vivo. Here, we investigated the property of the dimeric sICAM-1 as an inhibitor of LFA-1 interaction with ICAM-3, since the lower avidity of LFA-1 for ICAM-3 compared with ICAM-1 or ICAM-2 had been speculated. Using recently constructed heterodimeric sICAM-1 joined at the C terminus via an ${\alpha}$-helical coiled coil (ACID-BASE) (Jun, CD. et al., 2001, Proc Natl Acad Sci 98, 6830-6835), we also tested whether the structural integrity in dimer could affect the inhibitory action of sICAM-1. Engineered sICAM-1 dimer that contained intact ectodomain (E34/E34) significantly blocked SKW3 cell (LFA-$1^+$) binding to ICAM-3, but not to ICAM-1 and ICAM-2, indicating the lower avidity of LFA-1 to ICAM-3 than that of both ICAM-1 and ICAM-2. A one binding site knock out mutant (E34/K34) showed ${\sim}2$-fold reduction in efficiency compared with E34/E34 to inhibit cell binding. Interestingly, a one binding domain deletion mutant (E34/${\Delta}D1$-D2) showed significant reduction (${\sim}5$-fold) compare with E34/K34, suggesting that structural integrity, which is precluded in E34/${\Delta}D1$-D2, is necessary for optimal binding of dimeric sICAM-1 to LFA-1, thereby inhibiting LFA-1/ICAM-3-dependent adhesion. Furthermore, BIAcore affinity measurements revealed that E34/${\Delta}D1$-D2 bound to immobilized soluble open LFA-1 I domain with an ${\sim}3$-fold reduced affinity compared with E34/K34. Overall, our results demonstrate that maintaining the structural integrity in dimer is necessary for optimal binding of sICAM-1 to LFA-1, and further suggest the therapeutic potential of dimeric sICAM-1 to antagonize LFA-1/ICAM-3-mediated cellular events in vivo.
Choi, Yoon Jin,Lee, Dong Ho,Choi, Myung-Gyu,Lee, Sung Joon,Kim, Sung Kook,Song, Geun Am,Rhee, Poong-Lyul,Jung, Hwoon-Yong,Kang, Dae-Hwan,Lee, Yong Chan,Lee, Si Hyung,Choi, Suck Chei,Shim, Ki-Nam,Seol, KOREAN ACADEMY OF MEDICAL SCIENCE 2017 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.32 No.11
<P>This study compared the efficacy of DA-9601 (Dong-A ST Co., Seoul, Korea) and its new formulation, DA-5204 (Dong-A ST Co.), for treating erosive gastritis. This phase III, randomized, multicenter, double-blind, non-inferiority trial randomly assigned 434 patients with endoscopically proven gastric mucosal erosions into two groups: DA-9601 3 times daily or DA-5,204 twice daily for 2 weeks. The final analysis included 421 patients (DA-5204, 209; DA-9601, 212). The primary endpoint (rate of effective gastric erosion healing) and secondary endpoints (cure rate of endoscopic erosion and gastrointestinal [GI] symptom relief) were assessed using endoscopy after the treatment. Drug-related adverse events (AEs), including GI symptoms, were also compared. At week 2, gastric healing rates with DA-5204 and DA-9601 were 42.1% (88/209) and 42.5% (90/212), respectively. The difference between the groups was −0.4% (95% confidence interval, −9.8% to 9.1%), which was above the non-inferiority margin of −14%. The cure rate of gastric erosion in both groups was 37.3%. The improvement rates of GI symptoms with DA-5204 and DA-9601 were 40.4% and 40.8%, respectively. There were no statistically significant differences between the two groups in both secondary endpoints. AEs were reported in 18 (8.4%) patients in the DA-5204 group and 19 (8.8%) in the DA-9601 group. Rates of AE were not different between the two groups. No serious AE or adverse drug reaction (ADR) occurred. These results demonstrate the non-inferiority of DA-5204 compared to DA-9601. DA-5204 is as effective as DA-9601 in the treatment of erosive gastritis. Registered randomized clinical trial at ClinicalTrials.gov (NCT02282670)</P>